Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084448 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00084448: Clinical Trial Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00084448 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084448, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug. Giving celecoxib together with paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel together with celecoxib works in treating patients with recurrent or persistent platinum-resistant ovarian epithelial or primary peritoneal cancer.
Interventions
- DRUG paclitaxel
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-04 |
| Phase | Phase 2 |
Why NCT00084448 stopped before completion
NCT00084448 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00084448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00084448 about?
NCT00084448 is a clinical study titled "Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and may increase the effectiveness of paclitaxel by making tumor cells more sen...
What is the current status of trial NCT00084448?
This trial is currently terminated. It is a Phase 2 study. The study started on 2004-04.
What interventions are being tested in trial NCT00084448?
The interventions under investigation include: paclitaxel (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00084448?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia